Table 3.
HRCT findings in patients 4 months after COVID-19 (n = 63) and differences between patients who were not hospitalised, hospitalised without ICU and with ICU treatment.
| All (n = 64) | Group I (n = 12) | Group II (n = 38) | Group III (n = 14) | p-Value (between Groups) # | |
|---|---|---|---|---|---|
| Any GGO | 40 (62.5) | 1 (8.3) | 25 (65.8) | 14 (100) | <0.001 A |
| Only GGO | 12 (18.8) | 1 (8.3) | 11 (29.0) | 0 (0) | 0.027 D |
| >25% GGO * | 17 (26.6) | 0 (0) | 7 (18.4) | 10 (71.4) | <0.001 B |
| Fibrosis (PF + HC) | 28 (43.8) | 0 (0) | 14 (36.8) | 14 (100) | <0.001 A |
| Air trapping | 10 (15.6) | 2 (16.7) | 4 (10.5) | 4 (28.6) | 0.308 |
| Bronchiectasis | 20 (31.3) | 3 (25.0) | 8 (21.1) | 9 (64.3) | 0.013 C |
| Tracheobronchomalacia | 5 (7.8) | 0 (0) | 4 (10.5) | 1 (7.1) | 0.814 |
| Other ** | 22 (34.4) | 6 (50.0) | 11 (29.0) | 5 (35.7) | 0.441 |
Data are expressed as n (%). GGO: ground-glass opacities, PF: pulmonary fibrosis, HC: honeycombing. # Fisher’s exact test and if significant followed by bivariate comparison with Bonferroni correction for multiple comparisons. * In more than one zone; ** Noduli, enlarged truncus pulm, emfysem etc. A: Difference between all groups. B: Difference between not hospitalised and hospitalised with ICU and hospitalised without ICU and hospitalised with ICU. C: Difference between hospitalised without ICU and hospitalised with ICU. D: No difference between groups with Bonferroni correction.